SPYRE THERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
SPYRE THERAPEUTICS, INC. (SYRE) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-05-10
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2021-03-31 was $0.00.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month |
|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |